Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications
Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.
Journal: Neurodegenerative disease management
Published: May 20, 2026
Estimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 05, 2026
"We feel like we don't matter": the work experience of caring for long-term care residents with suspected trauma-related responsive behaviors.
Journal: BMC health services research
Published: February 13, 2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
Journal: Lancet (London, England)
Published: February 06, 2026
Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference.
Journal: Journal of the American Heart Association
Published: January 19, 2026
Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial.
Journal: The journal of prevention of Alzheimer's disease
Published: December 22, 2025
Safety considerations of gene-based therapies for Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: October 01, 2025
An International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer's disease.
Journal: Nature aging
Published: September 22, 2025
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: September 05, 2025
A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA.
Journal: The Lancet. Neurology
Published: September 05, 2025
Protocol for the Asian Cohort for Alzheimer's Disease (ACAD) Study.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: August 05, 2025
Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer's Disease Therapeutic Agent.
Journal: ACS pharmacology & translational science
Published: July 11, 2025
Last Updated: 09/26/2026